伴侣动物关节炎市场、机会、成长动力、产业趋势分析与预测，2024-2032

全球伴侣动物关节炎市场到 2023 年价值约 34 亿美元，2024 年至 2032 年复合年增长率将达到 7.2%。这种增长刺激了对伴侣动物保健产品的需求，包括药物和补充剂。美国宠物产品协会的全国宠物主人调查显示，约 8,690 万个美国家庭（即 66%）拥有宠物，从鸟类、猫到狗和雪貂。此外，全球收养宠物的增加，加上先进诊断工具和更有效的治疗选择等兽医技术的进步，推动了市场的成长。这些进步提高了治疗效果并扩大了可治疗疾病的范围。

兽医诊所越来越多地利用先进的影像技术，例如 MRI（磁振造影）和 CT（电脑断层扫描）扫描来诊断宠物的关节问题。这些工具使兽医能够更清晰地了解关节结构，从而製定更精确的治疗计划。此外，市场由创新的治疗技术和设备驱动，包括雷射治疗、客製化復健计画和活动监视器。

整个伴侣动物关节炎行业根据治疗类型、疾病类型、动物类型、最终用途和地区进行细分。

市场按治疗类型分为药物、食品补充剂、手术和其他治疗。到 2023 年，药品领域预计将达到 15 亿美元。为了减轻伴侣动物的关节炎症状，兽医通常会开一些药物，如非类固醇抗发炎药、皮质类固醇和缓解疾病的骨关节炎药物 (DMOAD)，强调缓解疼痛和减少发炎。兽医学的进步——从增强的诊断到强有力的药物和整体治疗方案——提高了关节炎治疗的有效性和可及性。

按疾病类型细分，伴侣动物关节炎市场包括骨关节炎、类风湿性关节炎和其他形式。 2023年，骨关节炎以64.3%的份额引领市场。骨关节炎在宠物中普遍存在，影响近 20% 的老年狗和猫，导致关节软骨退化和随后的骨骼变化。消费者对天然和整体疗法（例如葡萄糖胺、软骨素和 omega-3 脂肪酸等营养保健品）的倾向不断上升，这表明对治疗狗骨关节炎的产品的需求上升，从而推动市场成长。

2023 年，北美在全球伴侣动物关节炎市场中占据主导地位，占 45.6% 的份额，预测显示该市场将持续强劲成长。北美市场扩张的主要驱动力包括宠物拥有量的激增、动物健康意识的提高以及兽医护理的进步。随着宠物护理领域的发展，北美利益相关者——尤其是那些创新和满足独特市场需求的利益相关者——有望获得重大收益。

目录

第 1 章：方法与范围

第 2 章：执行摘要

第 3 章：产业洞察

• 产业生态系统分析
• 产业影响力
  • 成长动力
    • 收养宠物的趋势不断上升
    • 伴侣动物关节炎治疗的技术创新
    • 老年宠物关节炎盛行率增加
  • 产业陷阱与挑战
    • 与先进的诊断、药物和专门治疗相关的高成本
    • 研究和开发有限
• 成长潜力分析
• 技术景观
• 监管环境
• 波特的分析
• PESTEL分析

第 4 章：竞争格局

• 介绍
• 公司市占率分析
• 公司矩阵分析
• 主要市场参与者的竞争分析
• 竞争定位矩阵
• 战略展望矩阵

第 5 章：市场估计与预测：按治疗类型，2021 - 2032 年

• 主要趋势
• 药物
  • 非类固醇抗发炎药
  • 单株抗体
  • 其他药物
• 食品补充剂
• 手术
• 其他治疗类型

第 6 章：市场估计与预测：按疾病类型，2021 - 2032 年

• 主要趋势
• 骨关节炎
• 类风湿关节炎
• 其他关节炎类型

第 7 章：市场估计与预测：按动物类型，2021 - 2032

• 主要趋势
• 狗
• 猫
• 其他动物

第 8 章：市场估计与预测：按最终用途，2021 - 2032 年

• 主要趋势
• 兽医院
• 兽医诊所
• 兽医復健中心
• 其他最终用户

第 9 章：市场估计与预测：按地区划分，2021 - 2032 年

• 主要趋势
• 北美洲
  • 我们
  • 加拿大
• 欧洲
  • 德国
  • 英国
  • 法国
  • 西班牙
  • 义大利
  • 荷兰
  • 欧洲其他地区
• 亚太地区
  • 日本
  • 中国
  • 印度
  • 澳洲
  • 韩国
  • 亚太地区其他地区
• 拉丁美洲
  • 巴西
  • 墨西哥
  • 阿根廷
  • 拉丁美洲其他地区
• 中东和非洲
  • 南非
  • 沙乌地阿拉伯
  • 中东和非洲其他地区

第 10 章：公司简介

• American Regent, Inc.
• Bayer AG (Bayer Animal Health)
• Boehringer Ingelheim International GmbH
• CEVA Sante Animale
• Dechra Pharmaceuticals plc
• Elanco
• Eltech K-Laser s.r.l.
• Medivet
• Norbrook laboratories
• Nutramax Laboratories Veterinary Sciences, Inc
• Vetoquinol SA
• Vibrac
• Zoetis, Inc.

The Global Companion Animal Arthritis Market, valued at approximately USD 3.4 billion in 2023, is set to grow at a CAGR of 7.2% from 2024 to 2032. Increasing pet ownership is a primary driver for the market's growth. This rise has spurred demand for healthcare products for companion animals, including medications and supplements. The National Pet Owners Survey by the American Pet Products Association reveals that around 86.9 million American families, or 66%, own pets, spanning from birds and cats to dogs and ferrets. Moreover, the global uptick in pet adoption, coupled with technological strides in veterinary medicine-like advanced diagnostic tools and more potent treatment options-fuels market growth. These advancements boost treatment efficacy and expand the range of treatable conditions.

Veterinary clinics are increasingly utilizing advanced imaging techniques, such as MRI (magnetic resonance imaging) and CT (computed tomography) scans, to diagnose joint issues in pets. These tools offer veterinarians a clearer view of joint structures, allowing for more precise treatment plans. Furthermore, the market is driven by innovative therapeutic technologies and devices, including laser treatments, tailored rehabilitation programs, and activity monitors.

The overall companion animal arthritis industry is segmented based on treatment type, disease type, animal type, end-use, and region.

The market is segmented by treatment type into medication, food supplements, surgery, and other treatments. In 2023, the medication segment is projected to account for USD 1.5 billion. To alleviate arthritis symptoms in companion animals, veterinarians commonly prescribe pharmaceutical drugs like NSAIDs, corticosteroids, and disease-modifying osteoarthritis drugs (DMOADs), emphasizing pain relief and inflammation reduction. Advancements in veterinary medicine-ranging from enhanced diagnostics to robust medications and holistic treatment protocols-have improved the effectiveness and accessibility of arthritis treatments.

Segmented by disease type, the companion animal arthritis market includes osteoarthritis, rheumatoid arthritis, and other forms. In 2023, osteoarthritis led the market with a commanding 64.3% share. Osteoarthritis, prevalent in pets, impacts nearly 20% of older dogs and cats, leading to joint cartilage degeneration and subsequent bone changes. The rising consumer inclination towards natural and holistic remedies-like nutraceuticals such as glucosamine, chondroitin, and omega-3 fatty acids-signals an uptick in demand for products addressing osteoarthritis in dogs, thus propelling market growth.

North America held a dominant 45.6% share of the global companion animal arthritis market in 2023, with forecasts suggesting continued robust growth. Key drivers for North America's market expansion include surging pet ownership, increased awareness of animal health, and advancements in veterinary care. As the pet care landscape evolves, North American stakeholders-especially those innovating and addressing unique market needs-are poised for significant gains.

Table of Contents

Chapter 1 Methodology and Scope

• 1.1 Market scope and definitions
• 1.2 Research design
  • 1.2.1 Research approach
  • 1.2.2 Data collection methods
• 1.3 Base estimates and calculations
  • 1.3.1 Base year calculation
  • 1.3.2 Key trends for market estimation
• 1.4 Forecast model
• 1.5 Primary research and validation
  • 1.5.1 Primary sources
    • 1.5.1.1 Data mining sources

Chapter 2 Executive Summary

• 2.1 Industry 360° synopsis

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Rising trend of pet adoption
    • 3.2.1.2 Technological innovation in treatments of arthritis for companion animals
    • 3.2.1.3 Increasing prevalence of arthritis in aging pets
  • 3.2.2 Industry pitfalls and challenges
    • 3.2.2.1 High costs associated with advanced diagnostics, medications, and specialized treatments
    • 3.2.2.2 Limited research and development
• 3.3 Growth potential analysis
• 3.4 Technological landscape
• 3.5 Regulatory landscape
• 3.6 Porter's analysis
• 3.7 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

• 4.1 Introduction
• 4.2 Company market share analysis
• 4.3 Company matrix analysis
• 4.4 Competitive analysis of major market players
• 4.5 Competitive positioning matrix
• 4.6 Strategy outlook matrix

Chapter 5 Market Estimates and Forecast, By Treatment Type, 2021 - 2032 ($ Mn)

• 5.1 Key trends
• 5.2 Medication
  • 5.2.1 NSAIDs
  • 5.2.2 Monoclonal antibodies
  • 5.2.3 Other medications
• 5.3 Food supplement
• 5.4 Surgery
• 5.5 Other treatment types

Chapter 6 Market Estimates and Forecast, By Disease Type, 2021 - 2032 ($ Mn)

• 6.1 Key trends
• 6.2 Osteoarthritis
• 6.3 Rheumatoid arthritis
• 6.4 Other arthritis types

Chapter 7 Market Estimates and Forecast, By Animal Type, 2021 - 2032 ($ Mn)

• 7.1 Key trends
• 7.2 Dogs
• 7.3 Cats
• 7.4 Other animals

Chapter 8 Market Estimates and Forecast, By End-Use, 2021 - 2032 ($ Mn)

• 8.1 Key trends
• 8.2 Veterinary hospitals
• 8.3 Veterinary clinics
• 8.4 Veterinary rehabilitation centers
• 8.5 Other end-users

Chapter 9 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

• 9.1 Key trends
• 9.2 North America
  • 9.2.1 U.S.
  • 9.2.2 Canada
• 9.3 Europe
  • 9.3.1 Germany
  • 9.3.2 UK
  • 9.3.3 France
  • 9.3.4 Spain
  • 9.3.5 Italy
  • 9.3.6 Netherlands
  • 9.3.7 Rest of Europe
• 9.4 Asia Pacific
  • 9.4.1 Japan
  • 9.4.2 China
  • 9.4.3 India
  • 9.4.4 Australia
  • 9.4.5 South Korea
  • 9.4.6 Rest of Asia Pacific
• 9.5 Latin America
  • 9.5.1 Brazil
  • 9.5.2 Mexico
  • 9.5.3 Argentina
  • 9.5.4 Rest of Latin America
• 9.6 Middle East and Africa
  • 9.6.1 South Africa
  • 9.6.2 Saudi Arabia
  • 9.6.3 Rest of Middle East and Africa

Chapter 10 Company Profiles

• 10.1 American Regent, Inc.
• 10.2 Bayer AG (Bayer Animal Health)
• 10.3 Boehringer Ingelheim International GmbH
• 10.4 CEVA Sante Animale
• 10.5 Dechra Pharmaceuticals plc
• 10.6 Elanco
• 10.7 Eltech K-Laser s.r.l.
• 10.8 Medivet
• 10.9 Norbrook laboratories
• 10.10 Nutramax Laboratories Veterinary Sciences, Inc
• 10.11 Vetoquinol SA
• 10.12 Vibrac
• 10.13 Zoetis, Inc.